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Abstract (250 words max) 
The extracellular matrix (ECM) of adipose tissues undergoes constant remodelling to allow 
adipocytes and their precursor cells to change cell shape and function in adaptation to 
nutritional cues. Abnormal accumulation of ECM components and their modifiers in adipose 
tissues has been recently demonstrated to cause obesity-associated insulin resistance, a 
hallmark of type 2 diabetes. Integrins and other ECM receptors (e.g. CD44) that are 
expressed in adipose tissues have been shown to regulate insulin sensitivity. It is well 
understood that a hypoxic response is observed in adipose tissue expansion during obesity 
progression and that hypoxic response accelerates fibrosis and inflammation in white adipose 
tissues. The expansion of adipose tissues should require angiogenesis; however, the excess 
deposition of ECM limits the angiogenic response of white adipose tissues in obesity. While 
recent studies have focused on the metabolic consequences and the mechanisms of adipose 
tissue expansion and remodelling, little attention has been paid to the role played by the 
interaction between peri-adipocyte ECM and their cognate cell surface receptors. This review 
will address what is currently known about the roles played by adipose ECM, their modifiers, 
and ECM receptors in obesity and insulin resistance. Understanding how excess ECM 
deposition in adipose tissue deteriorates insulin sensitivity would provide us hints to develop 
a new therapeutic strategy for the treatment of insulin resistance and type 2 diabetes. 
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1. Introduction 
The global epidemic of overweight and obesity is escalating and has become a major 
health challenge. Obesity is implicated as a cause of many devastating diseases, including 
diabetes, cardiovascular disorders, and cancers [1]. Insulin resistance is a pathological 
condition closely associated with obesity, which may underlie the links between obesity and 
chronic metabolic diseases [2]. Adipocytes undergo dramatic expansion during the 
development of obesity. At the same time, the adipose tissue of obese individuals becomes 
fibrotic in both subcutaneous and omental fat depots [3,4]. Of note, obese insulin-resistant 
subjects with a similar body mass index display increased fibrosis in adipose tissues than 
obese insulin-sensitive subjects [5]. These studies suggest that fibrosis in the adipose tissue is 
closely associated with obesity and insulin resistance. However, how adipose tissue fibrosis 
occurs and exerts its metabolic impacts on the pathophysiology of obesity and insulin 
resistance is unknown. It is suggested that the excess deposition of extracellular matrix 
(ECM) components, such as collagens and osteopontin (OPN), in adipose tissues triggers the 
necrosis of adipocytes, which attracts classically activated pro-inflammatory macrophages 
and causes tissue inflammation and metabolic dysfunction (Figure 1). In addition to imposing 
physical restriction on adipose tissue expansion, excess ECM deposition may cause adipocyte 
death and adipose inflammation through the signalling via integrins and CD44. In this 
review, we summarize the recent findings on adipose tissue ECM remodelling and the roles 
played by ECM receptors, e.g. integrins, CD44, and CD36. We propose a new concept that 
the interaction of adipose ECM molecules with their cognate receptors expressed not only by 
adipocytes but also by a diverse array of cells, i.e. pre-adipocytes, macrophages, and vascular 
endothelial cells, should contribute to adipose tissue inflammation, apoptosis, angiogenesis, 
and subsequent metabolic deteriorations in obesity. A similar concept has been proposed in 
the biology of the skeletal muscle and liver, which was recently reviewed elsewhere [6]. 
5 
 
Despite a novel perception in the context of obesity and insulin resistance, ECM-ECM 
receptor pathways have been long implicated in the biology of pulmonary fibrosis, wound 
healing, and tumor growth [7-9]. 
 
2. ECM components in the adipose tissue 
2.1 Collagens 
Collagens, as the most abundant structural components of the ECM, not only support 
tissue architecture but also cell functions, including cell adhesion, migration, differentiation, 
morphogenesis, and wound healing [10]. In adipose tissues, it is known that the ECM 
undergoes constant remodelling to allow adipocytes to rapidly expand and shrink in parallel 
with weight gain and loss [11]. Abnormal expression of ECM components, modifiers, and 
receptors in adipose tissues is a hallmark of obesogenic adipose tissue remodelling (Table 1). 
Excessive collagen deposition in adipose tissues has been seen in various animal models of 
metabolic diseases. In genetically obese and diabetic db/db mice, the mRNA levels of a group 
of collagens (mainly types I, III, V, and VI) are increased in white adipose tissues, and high-
fat diet (HFD) further increases those collagen expressions [12]. Type VI collagen is highly 
enriched in adipose tissues, and its gene-targeted deletion (Col6a1) results in less restricted 
expansion of adipose tissues coupled with a substantial improvement in whole-body energy 
homeostasis [3]. The overexpression of a cleaved fragment of the α-3 chain of collagen VI 
(Col6a3), named endotrophin, in mice stimulates fibrotic collagen deposition in adipose 
tissues and triggers adipose inflammation and insulin resistance [13]. In obese humans, the 
expression of collagen V is increased in adipose tissues that demonstrate a decreased number 
of capillaries [14]. Increased collagen V is colocalized with blood vessels, and the addition of 
collagen V to an angiogenesis assay inhibits endothelial budding, suggesting an inhibitory 
role of collagen V in angiogenesis [14]. These data suggest that excessive collagen deposition 
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in adipose tissue poses physical barriers against adipocyte hypertrophy during obesity 
progression and may also inhibit angiogenesis within adipose tissues. 
 
2.2 Osteopontin 
Osteopontin (OPN), also known as secreted phosphoprotein 1, is an ECM 
glycoprotein expressed in various cell types and tissues including the adipose tissue [15]. 
OPN expression is drastically increased in adipose tissues of HFD-induced and genetically 
obese mice as well as obese humans [16]. OPN is highly expressed in adipose tissue 
macrophages [17]. The genetic deletion of OPN in mice prevents HFD-induced obesity 
[18,19] and attenuates macrophage infiltration in adipose tissues, improving insulin 
sensitivity [17]. Similarly, neutralization of OPN using a monoclonal OPN antibody [20] or 
OPN gene silencing selective to adipose tissue macrophages [21] in mice suppresses adipose 
tissue inflammation and insulin resistance. It is hypothesized that action of OPN is mediated 
through engagement of a number of receptors, but particularly through CD44 and integrin 
αvβ3 [15]. 
   
2.3 Hyaluronan 
Hyaluronan (HA) is a linear glycosaminoglycan consisting of chemically unmodified 
repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine [22]. HA 
binds to cell-surface receptors (CD44 and HA-mediated motility receptor) and influences 
cellular responses such as proliferation and migration [23]. HA content is increased in 
hypertrophic 3T3-L1 cells and in the adipose tissues of diabetogenic LDL receptor-deficient 
and ob/ob mice, possibly due to an increased expression of HA synthase 2 [24]. Increased 
HA content has been demonstrated to facilitate monocyte adhesion and chemotaxis [24]. In 
contrast, the reduction of HA by exogenous hyaluronidase inhibits adipogenesis of 3T3-L1 
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cells [25].  Moreover, chronic treatment of HFD-fed obese mice with a PEGylated human 
recombinant hyaluronidase PH-20 decreases adiposity and adipose inflammation to prevent 
insulin resistance [26].   
 
2.4 Thrombospondins 
Thrombospondin 1 (THBS1) is a large adhesive ECM glycoprotein expressed 
predominantly in visceral adipose tissues and its expression is elevated in insulin-resistant, 
obese humans [27,28]. In mice, HFD acutely induces Thbs1 expression in visceral adipose 
tissues and increases the circulating THBS1 level [29]. The genetic deletion of Thbs1 renders 
mice protected from adipose tissue inflammation and insulin resistance [29,30]. Most 
importantly, a recent study suggests that circulating THBS1 may induce fibrotic damage to 
skeletal muscle and insulin resistance as Thbs1-null skeletal muscles are protected from 
HFD-induced collagen deposition [29]. This is the first study that suggests a potential role of 
circulating ECM protein in the crosstalk between the adipose tissue and the skeletal muscle in 
obesity and insulin resistance. Despite the important role played by THBS1 in adipose tissue 
inflammation and insulin resistance, THBS2 does not seem to play a substantial role in 
adipose tissue development and HFD-induced obesity, at least in mice [31]. 
 
3. ECM modifiers in the adipose tissue 
3.1 MMPs 
Matrix metalloproteinases (MMPs), a family of calcium-dependent and zinc-
containing endopeptidase, are responsible for the degradation of virtually all ECM proteins 
[32,33]. MMPs play an essential role in regulating ECM remodelling in both normal 
physiology and diseases [33,34]. MMP family members are categorized into soluble 
collagenase (MMP1, -8, -13), gelatinase (MMP2, -9), stromelysin (MMP3, -10, -11), 
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matrilysin (MMP7, -26), membrane-type MMPs (MT-MMPs) (MMP14, -15, -16, -17, -24, -
25), and elastase (MMP12) [34].  Dysregulation of MMPs are implicated in the 
pathophysiology of obesity and diabetes in humans [35-37]. Plasma concentrations of 
gelatinases (MMP2 and -9), two major circulating MMPs, are increased in obese [38] and 
diabetic humans [39,40]. The adipose expression of MMP9 positively correlates with the 
homeostasis model assessment index of insulin resistance (HOMA-IR) in obese humans [37].  
The specific role played by each MMP in the pathogenesis of obesity and insulin 
resistance has not been fully defined. MMP expression in the adipose tissue is differentially 
regulated in HFD-fed obese mice [41,42]. A series of MMP gene targeting were tested in 
mice to determine the role of each MMP in obesity and diabetes, and the results have been 
variable. The genetic deletion of MMP3 (stromelysin-1) causes hyperphagia and obesity in 
HFD-fed mice [43]. The responsible substrate or the site of action of MMP3 in metabolism is 
unknown. MMP3 cleaves OPN [44]; therefore, the loss of MMP3 may exacerbate OPN-
dependent adipose inflammation. Similarly, MMP11 (stromelysin-3)-null mice are more 
prone to HFD-induced obesity [45]. The gene targeting of MMP10 (stromelysin-2) did not 
cause any significant changes in adipose tissue size and function after 15-week HFD [46].   
Mice lacking a gelatinase, MMP2 (gelatinase A), are resistant to obesity induced by 
HFD feeding, displaying smaller fat pads and smaller adipocytes [47]. The genetic deletion of 
another gelatinase, MMP9 (gelatinase B), however, did not demonstrate a significant change 
in weight, fat mass, fasting blood glucose and insulin levels after 15 weeks of HFD [48]. As 
MMP9 is highly expressed by adipose tissue macrophages [49], a further study should be 
needed to fully define the impact of genetic deletion of MMP9 on adipose inflammation and 
metabolism. Interestingly, a pharmacological inhibition of MMPs with a relative specificity 
to MMP2 and MMP9 reduces weight gain and fat pad weights in ob/ob mice [50].  
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Among MT-MMPs, MMP14 (MT1-MMP) and MMP15 (MT2-MMP) act as major 
pericellular collagenases [51]. The loss of MMP14 causes severe lipodystrophic phenotype, 
underscoring its dominant role in adipose tissue development in mice [52]. MMP14 
haploinsufficiency confers mice a protection from diet-induced obesity and a genetic variance 
in human MMP14 gene is associated with obesity and diabetes [36]. While MMP14 is the 
major regulator of MMP2 activation [53], the gene deletion of both MMP2 and MMP14 
causes a synthetic lethality, underscoring the critical biological pathways regulated through 
the interplay between MMP2 and MMP14 [54]. In humans, MMP15 (MT2-MMP) is down-
regulated in white adipose tissues of obese humans [37]. The exact role of MMP15 in 
regulating adipose tissue size and function is unknown. Unlike MMP14, the gene deletion of 
MMP15 alone does not cause a significant developmental defect; however, the loss of both 
MMP14 and -15 causes embryonic lethality due to the defective development of the placenta 
[55]. As such, the functional interplay of MMP14 with MMP2 and/or MMP15 may play a 
synergistic role in regulating adipose tissue function as well. The roles played by other MT-
MMPs (MMP16, -17, -24, -25) in the regulation of obesity and diabetes are unknown.   
Elastin is another major component of adipose ECM [56]. The expression of elastin in 
adipose tissues was found to be less abundant in obesity [14].  MMP12 (macrophage elastase) 
is the major MMP that degrades elastin in mice [57].  In HFD (60% fat)-induced obesity, 
adipose macrophages, particularly CD11c- residential macrophages (M2-like) express a high 
level of MMP12 [58,59]. In their study, the loss of MMP12 exacerbated HFD-induced 
adipose hypertrophy but improved insulin sensitivity [58]. The loss of MMP12 alone, 
however, did not change elastin content in adipose tissues under either normal or HFD 
condition [59].  Another group reported that the loss of MMP12 did not exert any significant 
effects on HFD (42% fat)-induced obesity [60]. It is unclear whether a difference in dietary 
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fat content or genetic background may account for the difference in the reported obesity 
phenotypes.  
Together, these data suggest that MMPs play important but diverse roles in regulating 
adipose tissue homeostasis in obesity; however, the exact substrates of each MMP 
responsible for the regulation of obesity and diabetes phenotypes have not been fully defined. 
The functional interplays between MMPs, e.g. MMP2 and -14, MMP14 and -15, in the 
regulation of adipose tissue homeostasis and metabolism should require further investigation. 
 
3.2 TIMPs 
The MMPs are inhibited by specific endogenous tissue inhibitors of 
metalloproteinases (TIMPs), which comprise a family of four protease inhibitors: TIMP-1, -2, 
-3 and -4 [61]. Circulating levels of TIMP-1 and -2 are increased in patients with metabolic 
syndrome and diabetes [40]. Hypothalamic TIMP-1 expression is regulated by an adipose-
derived hormone, leptin, and the gene deletion of TIMP-1 causes increased food intake and 
obesity in female mice [62]. The overexpression of TIMP-1 in pancreatic β-cells protects 
mice from streptozotocin-induced β-cell death and diabetes [63]. While TIMP-1 mostly 
inhibits soluble MMPs alone, TIMP-2 can inhibit both soluble and MT-MMPs [51]. The 
genetic deletion of TIMP-2 in mice exacerbates HFD-induced obesity and diabetes [64]. 
TIMP-2 gene deletion impairs MMP14 (MT1-MMP)-dependent MMP2 activation [65]; 
therefore, the phenotype of TIMP-2-null mice might be partly modified by the impaired 
MMP2 activation. TIMP-3 expression is reduced in the adipose tissue of mouse obesity 
models [42]. The genetic deletion of TIMP-3 in mice causes hepatic steatosis and adipose 
tissue inflammation [66], whereas TIMP-3 overexpression in macrophages protects mice 
from insulin resistance, adipose inflammation, and hepatic steatosis [67].  
These data may suggest that increased activities of TIMPs in tissues are protective in 
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metabolic regulation, but in a tissue- and context-dependent manner. While TIMPs are 
endogenous inhibitors of MMPs that are responsible for degrading excess ECM, it is unclear 
whether the beneficial effects of increased TIMP activities is solely due to the suppressed 
activity of MMPs and increased ECM stability or through different target molecules, 
including ADAM (a disintegrin and metalloproteinase) and ADAMTS (a disintegrin and 
metalloproteinase with thrombospondin motifs) [68].  
 
4. ECM receptors in the adipose tissue 
4.1 Integrins 
Integrins are heterodimeric transmembrane receptors ensuring the communication 
between ECM and the intracellular environment. In mammals, there are eighteen α and eight 
β subunits that can be non-covalently assembled into 24 heterodimeric combinations [69]. 
The specific integrin expression patterns determine which ECM substrate can bind to the cell 
and further regulate the downstream signalling events. In brief, integrins are classified into 
several subfamilies including collagen receptors, laminin receptors, Arg-Gly-Asp (RGD) 
receptors and leukocytes-specific receptors [69]. Collagen and laminin receptor integrins 
share common β1 subunit and leukocyte-specific receptor integrins share common β2 
subunit. It has been shown that integrin β1 is critical in regulating HFD-induced insulin 
resistance in skeletal muscles [70,71]; however, its role in adipose tissues has not been 
studied. On the other hand, leukocyte-derived β2 integrin has been associated with HFD-
induced obesity and insulin resistance in adipose tissue. Under a HFD condition, mutated β2-
integrin knockin mice display increased neutrophil numbers in white adipose tissues and 
show significantly increased peripheral insulin resistance [72]. The β2 integrin subfamily is 
comprised of 4 members, αLβ2 (CD11a/CD18), αMβ2 (CD11b/CD18), αXβ2 
(CD11c/CD18), and αDβ2 (CD11d/CD18). CD11b, CD11c and CD11d expression is 
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increased in adipose tissue and circulating monocytes of obese humans and rodents [73-75]. 
The majority of macrophages infiltrated in white adipose tissue in obesity co-express CD11b 
and CD11c [76]. Moreover, CD11b deficient mice are protected from development of HFD-
induced insulin resistance through reduction of alterative activation and proliferation of 
adipose tissue macrophages [77]. CD11c-positive adipose tissue macrophages are identified 
as markers of insulin resistance in human obesity [78]. These studies are consistent and may 
suggest a contributing role of β2 integrin expressed by neutrophils and macrophages in diet-
induced insulin resistance. Integrin α4 associates with either β1 or β7 subunit to form an 
integrin that may play a role in cell motility and migration [79]. Although inhibiting α4 
integrin function and signalling has been shown to block inflammatory responses associated 
with mononuclear cell-mediated diseases such as multiple sclerosis and Crohn's disease 
[80,81], their role in low-grade chronic inflammatory conditions, such as obesity-induced 
insulin resistance is not well studied. However, it is shown that mice bearing an α4 (Y991A) 
mutation are protected from development of HFD-induced insulin resistance through 
mediating the trafficking of monocytes into adipose tissues [82]. 
  
4.2 CD44 
CD44 is a multifunctional cell membrane receptor for ECM components, mainly HA 
and OPN [83]. CD44 transcripts are subject to alternative splicing, resulting in the expression 
of CD44 standard isoform (CD44s) and multiple CD44 variants (CD44v) [84]. CD44s is 
ubiquitously expressed in most tissues, whereas the larger variant isoforms are expressed 
only in a few epithelial tissues and several cancers [85]. The expression of CD44v in adipose 
tissues has not been identified and studied. Current studies of CD44 in adipose tissue in the 
context of obesity and diabetes have focused on the standard form of CD44. CD44s is 
associated with type 2 diabetes from expression-based genome-wide association studies [86]. 
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CD44s expression level in adipose tissue is positively correlated with adipose inflammation 
and an index of insulin resistance, HOMA-IR in obese individuals and HFD-fed obese mice 
[86-88]. Serum CD44s levels are positively correlated with insulin resistance and glycemic 
control in human subjects [86]. HFD-fed CD44 knockout mice remain considerably more 
insulin sensitive and glucose tolerant than HFD-fed wildtype control mice and exhibit lower 
blood insulin levels [89]. Treatment of CD44 monoclonal antibody suppresses visceral 
adipose tissue inflammation and reduces fasting blood glucose levels, weight gain, liver 
steatosis, and insulin resistance in a HFD-fed mouse model [88]. These of course cannot rule 
out the potential expression and importance of CD44v in adipose tissue of obesity and insulin 
resistance. 
 
4.3 CD36 
CD36 also known as fatty acid translocase is an integral membrane protein, which 
binds many ligands including collagen, THBS, lipoproteins and fatty acids [90]. CD36 
facilitates FFA transport into adipose tissue in humans [91].  HFD-fed mice harbouring CD36 
deletion display improved insulin signalling and reduced macrophage infiltration in adipose 
tissue compared with wildtype mice, with variable effects on HFD-induced whole-body 
insulin resistance [92-94]. Genetic variation within the CD36 locus is suggested to contribute 
to metabolic disease via its effect on body adiposity [95]. Gene expression studies indicate 
that CD36 is significantly upregulated in the mesenteric adipose tissue of diabetic patients 
[96]. AP5258, a CD36 specific inhibitor significantly increases cell survival of oleic acid-
treated mouse and human adipocytes, and partially restores the transcriptional response to 
oleic acid in the presence of insulin through JNKs (c-Jun N-terminal kinases) pathway [97]. 
Although most of these studies of CD36 in adipose tissue in obesity and insulin resistance are 
attributed to its role as a FFA transporter, the role of ECM binding in the process of FFA 
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uptake is potentially significant. This is evidenced by the fact that an ECM ligand, such as 
THBS induces the dimerization of membrane-bound CD36, which is proposed to play an 
important role in signal transduction [98].  
 
5. Proposed model for how ECM-receptor interaction is linked to obesity-associated 
insulin resistance 
Numerous studies have demonstrated that the increased deposition of ECM 
components and the presence and activation of ECM receptor pathways in adipose tissue are 
associated with obesity-associated inflammation and insulin resistance. The underlying 
mechanisms however, are not fully understood. We propose the following potential 
downstream pathways of ECM-receptor signalling that may mediate the process. These 
include induction of adipocyte death, inhibition of angiogenesis in adipose tissues and the 
promotion of inflammatory cytokine production and macrophage infiltration (Figure 2). It is 
worth noting that these pathways share analogies to those leading to pulmonary fibrosis, 
wound healing and tumor growth [7-9]. Similarities and differences of adipose ECM 
remodelling in comparison to cancer ECM dynamics are highlighted in the following section. 
 
5.1 Induction of adipocyte death 
The ECM in the adipose tissue surrounding adipocytes not only provides structural 
support but regulates cell proliferation and death. Adipocyte death is increased progressively 
during the development of obesity with a frequency of 80% death rate in mice after 16 weeks 
of HFD feeding, coincident with widespread deposition of collagen [99]. It is hypothesized 
that excessive deposition of adipose ECM components physically constraints the expansion 
of adipocytes and cause adipocyte death [3]. We hypothesize that ECM receptor pathways 
(e.g. integrins) would trigger downstream gene regulation that mediates processes that 
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regulate adipocyte necrosis or apoptosis. This hypothesis is supported by the fact that ob/ob 
mice that lack collagen VI (Col6a1) display a reduced necrotic cell death accompanied by 
enlarged adipocytes and improved systemic insulin resistance [3]. Reduced adipocyte death 
in these mice is associated with a significant reduction of spliced form of Xbp1, a marker for 
endoplasmic reticulum stress which causes cells to undergo apoptosis through activation of 
CHOP and JNK [3]. Adipocyte death may cause adipose inflammation and insulin resistance 
because necrotic adipocytes become a phagocytic stimulus that attracts macrophages [99].  
The concept that augmented ECM receptor signalling in adipose tissue induces 
adipocyte death is at odds with its proposed role in tumor biology. Many of the changes in the 
ECM, ECM modifiers and ECM receptors in expanding adipocytes occur during tumor cell 
growth including increased deposition of various collagens (e.g. I, II, III, V and IX) [9], 
increased levels of MMPs (e.g. MMP1, 2, 3, 7, 9, 12, 14, 21, 24, 25) and TIMPs (e.g. TIMP 
1, 2, 3) [100], and increased ECM receptor signalling (e.g. hyaluronan and CD44 signalling) 
[101]. However, it is shown that these ECM remodelling in cancer are to facilitate tumor cell 
growth, invasion, and metastasis [9,101]. In cancer, activated integrin signalling upon ECM 
binding initiates pro-survival signals through increased nuclear factor-κB (NF-κB) or PI3K-
AKT activity, decreased p53 activation and increased expression of the pro-survival 
molecules BCL-2 and FLIP [102]. Although disparate from our proposal that activated ECM 
signalling in adipose tissue would cause adipocyte death and associated inflammatory 
response (Figure 2), research in cancers would provide insight to our understanding of 
adipose tissue biology in obesity and insulin resistance. 
 
5.2. Inhibition of angiogenesis in adipose tissue 
White adipose tissues are highly vascularised and expansion of adipose tissue is 
necessarily accompanied by angiogenesis. It is hypothesized that excessive deposition of 
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ECM limits the angiogenic capacity of white adipose tissue in obesity. It is shown that the 
hypoxic response in the adipose tissue of ob/ob mice is paradoxically associated with 
decreased gene expression of vascular endothelial growth factor A (VEGFa), vascular 
endothelial cell markers, and decreased vessel density [103]. Overexpression of dominant 
active hypoxia inducible factor 1 (HIF1) fails to increase VEGFa expression but induces the 
gene expression causal for tissue fibrosis [103]. Likewise, overexpression of VEGFa leads to 
increased adipose vascularity and reduced tissue hypoxia [104]. These findings are in contrast 
to what is found in cancers wherein hypoxia stimulates angiogenesis via HIF1a/VEGFa 
pathway [105], and suggest the presence of an obesity-specific relationship between hypoxia, 
fibrosis, and angiogenesis. Moreover, increased collagen V inhibits endothelial budding, 
suggesting its inhibitory role in angiogenesis [14]. As adipose tissue fibrosis inhibits the 
angiogenic capacity of the tissue, it is reasonable to propose that the suppressed expression of 
genes necessary for adipose angiogenesis (e.g. VEGFa) should be mediated by the activation 
of ECM receptor pathways by excess ECM deposition. We have previously showed that 
genetic deletion of integrin α2β1, one of the collagen binding receptors is associated with 
increased vascularization in muscle of HFD-induced obese mice [70]. The angiogenic 
capacity of white adipose tissues is positively associated with glucose homeostasis. Mice 
with adipose-specific deletion of VEGFa display exacerbated insulin and glucose tolerance 
on a HFD; in contrast, induction of VEGFa expression in adipose tissue reverses glucose 
intolerance in HFD-induced obese mice [104]. It is hypothesized that reduced angiogenesis in 
white adipose tissues leads to reduced exchange of insulin and other hormones, cytokines and 
adipokines from blood to fat, leading to insulin resistance. Although not specifically shown in 
adipose tissue, we have successfully demonstrated such a relationship in an insulin-sensitive 
metabolic tissue, i.e.,  the skeletal muscle . Our previous studies have shown that defects in 
recruitment of muscle capillaries contribute to the development of muscle insulin resistance 
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[106,107]; whereas improved muscle insulin resistance is associated with increased muscle 
capillary density [26,70]. Further studies are needed to investigate the metabolic impacts of 
integrin-dependent regulation of angiogenesis in adipose tissues. 
Transcriptional co-activators PGC-1α and PGC-1β have been shown to induce VEGF 
expression and angiogenesis in muscles [108-111]. As these two PGC-1 isoforms are 
operative in white adipose tissues, it is possible that inhibition of angiogenesis in obese, 
expanding adipocytes is due to decreased expression and function of PGC-1α and PGC-1β. 
This hypothesis is highly supported by the fact that the expression of both PGC-1α and PGC-
1β is decreased in obesity and mice lacking PGC-1α specifically in adipose tissue develops 
exacerbated insulin resistance on a HFD [112,113]. However, the role of ECM receptor 
pathways in the regulation of PGC-1 isoform expression is still unknown and may require 
further investigations. 
Angiogenesis is another shared pathway which is proven to be important in both 
obesity and cancer. Anti-angiogenesis therapy for cancers has been proposed for more than 
40 years; however, in both preclinical and clinical settings, the arise of resistance 
mechanisms limits the long-term benefit of anti-angiogenesis therapy [114]. In obesity, the 
therapeutic angiogenesis for treatment of obesity and metabolic diseases remains a 
paradoxically disputed issue [115]. Controversial results exist. For example, early studies 
using genetic and HFD-induced obese mice show that treatment of generic angiogenesis 
inhibitors including TNP-470 and angiostation, suppresses adipose angiogenesis and prevents 
obesity in mice [116,117]. In contrast, systemic anti-VEGF-A treatment to HFD-fed mice 
induced weight gain and caused exacerbated systemic insulin resistance [118]. Targeting 
angiogenesis in white adipose tissues for treating obesity and insulin resistance remains 
controversial and has been well reviewed previously [115]. 
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5.3 Induction of adipose tissue macrophage infiltration and inflammation 
We propose that activation of ECM binding to ECM receptor mediates intracellular 
signalling to regulate expression of genes that mediate inflammation and adipose tissue 
macrophage infiltration. Focal adhesion kinase (FAK), a ubiquitously expressed tyrosine 
kinase, which is essential for development and cellular proliferation, transmits extracellular 
signals via integrin signalling. Adipocyte-specific deletion of FAK increases adipose tissue 
inflammation shown by increased macrophage infiltration and adipocyte apoptosis [119]. 
These results suggest that FAK may be essential for gene expression for adipose tissue 
remodelling and inflammation. Chronic treatment of human recombinant peyglated 
hyaluronidase decreases adipose tissue ECM HA and decreases adipocyte size and the gene 
expression of pro-inflammatory markers (e.g. TNFα) in adipose tissue of HFD-fed mice [26]. 
Genetic deletion of the main HA receptor CD44 consistently decreases adipose tissue 
inflammation in mice following a HFD [89]. These results suggest that the activation of HA-
CD44 pathway regulates macrophage infiltration and inflammation in adipose tissue of HFD-
fed mice. It has been previously shown that the genetic deletion of β2 integrin CD11b 
protects mice from development of HFD-induced insulin resistance by suppressing the 
alterative activation and the proliferation of adipose tissue macrophages [77]. 
 
6. Concluding remarks 
It is recently ascertained that fibrosis, excess deposition of ECM components, in 
metabolically active, insulin-sensitive tissues, including the skeletal muscle, adipose tissue 
and liver has damaging impact on glucose homeostasis [6,120,121]. Obesogenic ECM 
remodelling of white adipose tissues is closely linked with the increased levels of circulating 
ECM proteins and ECM-derived peptides in parallel with increased levels of adipose-derived 
cytokines. These white adipose tissue-derived ECM or ECM-related molecules may exert 
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metabolically deleterious effects on metabolic crosstalk between the adipose tissue, liver, and 
skeletal muscles (Figure 3). Despite a recent implication of ECM-receptor pathway in 
determining glucose homeostasis in the skeletal muscle and liver [6], its role in the adipose 
tissue has not been fully defined. We postulate that the ECM receptor pathway of adipocytes 
as well as other cell types found in adipose tissues, i.e. inflammatory monocytes and 
macrophages and vascular endothelial cells are important in transducing intracellular 
signalling of adipocyte death, angiogenesis, and the infiltration of inflammatory cells, which 
culminate in insulin resistance. Tissue-specific mouse models that lack a key ECM, ECM 
modifier, ECM receptor, or intracellular mediator, will help us decipher the importance of the 
ECM receptor pathway and its regulators in determining metabolic tissue remodelling, 
function and glucose homeostasis. 
We propose the potential of developing therapeutic strategies that target ECM matrix 
of metabolically active tissues, including the liver, skeletal muscle and adipose tissue. 
Current anti-fibrotic drugs being tested in clinical settings have been focused on cancers (e.g. 
PEGPH20), heart failure (e.g. FT011) and glaucoma surgery (e.g. CLT-28643). The 
effectiveness of their use in obesity, insulin resistance and type 2 diabetes is unknown and 
may worth further investigation.  
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Figure Legends 
Figure 1 Adipose tissue remodelling during the development of obesity. 
Adipose tissues undergo dramatic remodelling during the development of obesity. These 
include enlargement of adipocytes, accumulation of extracellular matrix components, 
increased formation of new blood vessels and increased perfusion of capillaries, and 
increased infiltration of pro-inflammatory macrophages (M1-like). 
 
Figure 2 Proposed model for how the activation of ECM receptor pathway in adipose 
tissue is linked to obesity-associated insulin resistance. 
It is proposed that activation of ECM-receptor pathway would induce the expression of genes 
that mediate the metabolically unfavourable processes, including adipocyte death, inhibition 
of angiogenesis and attraction of pro-inflammatory macrophage infiltration which culminate 
in insulin resistance. Potential downstream intracellular signalling partners of each ECM 
receptor include FAK for integrin receptors [119], ERM for CD44 receptor [85] and MAPKs 
for CD36 receptor [122]. ECM: extracellular matrix; FAK: focal adhesion kinase; ERM: 
ezrin-radixin-moesin; MAPKs: mitogen-activated protein kinases; VEGF: vascular 
endothelial growth factor; ATM: adipose tissue macrophage. 
 
Figure 3. Fibrotic and inflammatory white adipose tissue remodelling in crosstalk with 
the liver and skeletal muscles. 
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Fibrotic and inflammatory adipose tissue remodelling is associated with the increased 
circulating levels of THBS1, OPN, endotrophin in parallel with IL6 and TNFα. These 
circulating factors derived from expanding adipose tissues induce insulin resistance of the 
liver and skeletal muscles.  
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Table 1. The ECM, ECM modifiers and ECM receptor remodelling in adipose tissue of 
obesity and insulin resistance. 
 
  
  Mice Human References 
ECM Collagen I, III, V, 
and VI 
↑ (db/db; 
ob/ob; 
HFD) 
 
↑ [3,12,14] 
Osteopontin ↑ (db/db; 
HFD) 
↑ [16,17]  
Hyaluronan ↑ (ob/ob; 
HFD) 
 [24] 
Thrombospontin 1 ↑ (HFD) ↑ [27,29] 
ECM 
modifier 
MMP2, 3, 11, 12, 
13, 14, 19 
↑ (HFD, 
ob/ob, 
db/db) 
 [41,42] 
MMP7, 16, 24 ↓ (HFD, 
ob/ob, 
db/db) 
 [41,42] 
MMP9 ↓ (HFD) ↑ [37,41] 
MMP15  ↓ [37] 
TIMP-1 ↑ (HFD)  [41] 
TIMP-2 ↓ (HFD 
males) 
 [64] 
TIMP-3 ↓ (ob/ob, 
db/db) 
 [42] 
TIMP-4 ↓ (HFD)  [41] 
ECM 
receptor 
β2 integrin (αLβ2, 
αMβ2, αXβ2, and 
αDβ2) 
↑ (HFD) ↑ [64] 
CD44 ↑ (HFD) ↑ [86-88] 
CD36  ↑ [96] 
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